Metabolic syndrome & psychiatric disorders

Indian Journal of Medical Research

Volumn 128, Issue 3, 2008, Pages 237-245

  Singh, S M ^a   Mattoo, S K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Metabolic syndrome; Psychotropic medication; Severe mental illness

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; BODY MASS; CARBOHYDRATE CRAVING; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EATING DISORDER; EDEMA; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; KINESIOTHERAPY; LIFESTYLE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

HUMANS; MENTAL DISORDERS; METABOLIC SYNDROME X; PSYCHOTROPIC DRUGS;

EID: 58549108475     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Lambert TJR, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8.
2. Czobor P, Volavka J, Sheitman B, Lindenmayer J, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002; 22: 244-51.
3. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Res 2003; 1: 19-27.
4. Jakovlejic M, Crncevic Z, Ljubicic D, Babic D, Topic R, Saric M. Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19: 76-86.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
7. Reaven GM. Syndrome X. Blood Press 1992; 4 (Suppl): 13-6.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultant. Diabet Med 1998; 15: 539-53.
9. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (executive summary). Circulation 2005; 112: 2735-52.
11. Alberti KGM, Zimmet P, Shaw J. Metabolic syndrome - a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
12. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33: 351-75.
13. Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in south Asians: continuing escalation and possible solutions. Indian J Med Res 2007; 125: 345-54.
14. Ramachandran A, Snehlata C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults-a population study using modified ATP III criteria. Diabetes Res Clin Pract 2003; 60: 199-204.
15. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 2003; 61: 69-76.
16. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai urban rural epidemiology study (CURES-34). Diabetes Metab Res Rev 2007; 23: 127-34.
17. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-31.
18. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8.
19. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 2003; 78: 447-56.
20. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005; 111: 1448-54.
21. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-7.
22. Dandona P, Aljada A, Bandopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
23. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8-year follow-up study of 14719 initially healthy American women. Circulation 2003; 107: 391-7.
24. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145-50.
25. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-65.
26. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002; 87: 1419-22.
27. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000; 85: 2970-3.
28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science 1993; 259: 87-91.
29. Hotamisligil GS, Perladi P, Budvari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity induced insulin resistance. Science 1996; 271: 665-8.
30. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003; 300: 1574-7.
31. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231: 235-40.
32. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. Hypertension 1997; 30: 1144-9.
33. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-81.
34. Montague C, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883-8.
35. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
36. Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2422-9.
37. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-200.
38. Bjorntorp P, Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann N Y Acad Sci 1999; 892: 297-307.
39. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002; 106: 2659-65.
40. Helz JW, Templeton B. Evidence of the role of psychosocial factors in diabetes mellitus: a review. Am J Psychiatry 1990; 147: 1275-82.
41. Wales JK. Does psychological stress cause diabetes? Diabet Med 1995; 12: 109-12.
42. Anderson R, Freedland KE, Close RF. The prevalence of comorbid depression in adults with diabetes. Diabetes Care 2001; 24: 1069-78.
43. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 1996; 23: 876-9.
44. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-20.
45. Regenold WT, Thapar RK, Marano C. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar 1 affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26.
46. Dixon W, Weiden P, Delhanty J. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-12.
47. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med 2005; 67 (Suppl): s26-s28.
48. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997; 154: 1497-503.
49. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illness. Prim Care Companion J Clin Psychiatry 2004; 6: 152-8.
50. McCarron RM, Keenen CR. The metabolic syndrome. In: Bermudes RA, Keck PE, McElroy SL, editors, Managing metabolic abnormalities in the psychiatrically ill. Washington, DC: American Psychiatric Publishing, Inc; 2007. p. 25-52.
51. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab 2006; 91: 718-21.
52. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
53. Vanina Y, Podolskya A, Sedky K, Shahab H, Siddiqui A, Munshi F et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842-7.
54. Brady K: Weight gain associated with psychotropic drugs. Southern Med J 1989; 82: 611-7.
55. Allison D, Mentore J, Heo M, Chandler LP, Cappeleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
56. Umbricht D, Pollack S, Kane J. Clozapine and weight gain. J Clin Psychiatry 1994; 55: 157-60.
57. Meltzer H. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59:17-22.
58. Wetterling T, Mubigbrodt H. Weight gain: side effect of atypical neuroleptics. J Clin Psychopharmacol 1999; 19: 316-21.
59. Ganguli R, Brar J, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr Res 2001; 49: 261-7.
60. Borison R, Arvanitis L, Miller B, Barbara G. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158-69.
61. Sachs G. "Sanity versus vanity": balancing the problem of weight gain and the benefits of psychotropic drugs. Therap Adv Psychoses 1999; 7: 5.
62. Vendsborg P, Bech P, Rafaelsen O. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139-47.
63. Brady K: Weight gain associated with psychotropic drugs. Southern Med J 1989; 82: 611-7.
64. Sussman N, Ginsberg D. Effect of psychotropic drugs on weight. Psychiatr Ann 1999; 29: 580-94.
65. Davis R, Peters D, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-42.
66. Dinesen H, Lennart G, Andersen T. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-9.
67. Joffe R, Post R, Uhde T. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986; 47: 313-4.
68. Rosenfeld W, Shaefer P, Pace K. Weight loss patterns with topiramate therapy. Epilepsia 1997; 38: 60-3.
69. Berken G, Weinstein D, Stern W. Weight gain: a side effect of tricyclic antidepressants. J Affect Dis 1984; 7: 133-8.
70. Gorman J. Mirtazapine: clinical overview. J Clin Psychiatry 1999; 60: 9-12.
71. Physicians' desk reference. Montvale, NJ: Medical Economics Data Production Company; 2000.
72. Gardner E. Effect of bupropion on weight in patients intolerant to previous antidepressants. Curr Therap Res 1984; 35: 188-99.
73. Delgano P, Charney D, Price L, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 1990; 47: 411-8.
74. Fava M, Judge R, Hoog SL, Nilsson ME, Kohe SC. Fluoxetine vs sertraline and paroxetine in major depressive disorder: changes in weight with long term treatment. Br J Psychiatry 2001; 1787: 304-10.
75. Rosalinda T. Change in weight during a one-year trial with fluoxetine. J Clin Psychiatry 1992; 53: 259-67.
76. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappeleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215-20.
77. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137-41.
78. Kato M, Gonzalez-Blanco M, Sotelo J. Metabolic syndrome in schizophrenia: a pilot study. Presented at the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, California, USA.
79. Littrell K, Perry R, Hilligoss N. Insulin resistance and syndrome X among schizophrenic patients. Presented at the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, California, USA.
80. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-9.
81. Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Takala JK. Metabolic syndrome in a middle-aged Finnish population. J Cardiovasc Risk 1997; 4: 291-5.
82. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Järvelin MR, Laurén LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005; 66: 559-63.
83. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007; 7: 14-20.
84. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore J. Atypical antipsychotics and visceral fat distribution in first episode, drug-naive patients with sciiizophrenia. Life Sci 2004; 74: 1999-2008.
85. Zhang Z-J, Yao, Z J, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58-62.
86. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. Encephale 2005; 31: 507-16.
87. Meltzer H. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001; 62 (Suppl 27): 35-9.
88. Lambert TJR, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8.
89. Lieberman J, Phillips M, Hongbin G, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first episode schizophrenia: a 52 week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacol 2003; 28: 995-1003.
90. Mukherjee S, Schnur D B, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; i 495.
91. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose and elevation of cortisol in drug-naive first-episode schizophrenia. Am J Psychiatry 2003; 160: 284-9.
92. Holsboer F. The endocrinology of mental disease. In: Grossman A, editor. Clinical endocrinology. Oxford: Blackwell Science; 2003 p. 1096-11C.
93. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
94. Heiskanen TH, Niskanen LG, Hinitikka JJ, Koivumma-Honkanen HT, Honkalampi KM, Viinamaki HT. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006; 67: 1422-7.
95. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002; 51: 1573-7.
96. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the third national health and nutrition examination survey. Psychosom Med 2004; 66: 316-22.
97. Herva A, Rasanen P, Miettunen J, Timonen M, Lasky K, Veijola J, et al. Co-occurrence of metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 birth cohort study. Psychosom Med 2006; 68: 213-6.
98. Skilton MR, Moulin P, Terra J-L, Bonnet F. associations between anxiety, depression and metabolic syndrome. Biol Psychiatry 2007; 62. 1251-57.
99. Istvan J, Zavela K, Weidner G. Body weight and psychological distress in NHANES I. Int J Obes Relat Metab Disord 1992; 16: 999-1003.
100. Ross CE. Overweight and depression. J Health Soc Behav 1994; 35: 63-79.
101. Crisp AH, McGuiness B. Jolly fat: relation between obesity and psychoneurosis in general population. BMJ 1976; 1: 7-9.
102. Palinkas LA, Wingard DL, Barrett-Connor E. Depressive symptoms in overweight and obese older adults: a test of the "jolly fat" hypothesis. J Psychosom Res 1996; 40: 59-66.
103. Roberts RE, Deleger S, Strawbridge WJ, Kapla GA. Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord 2003; 27: 514-21.
104. Garcia-Portilla MP, Saiz PA, Benabarre A, Sierra P, Perez J, Rodriguez A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008; 106: 197-201.
105. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61: 179-84.
106. Elmslie JL, Mann JI, Silverstone, JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486-91.
107. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich JGS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207-13.
108. Babic D, Jakovljevic M, Martinac M, Saric M, Topic R, Maslov B. Metabolic syndrome and combat post-traumatic stress disorder intensity: preliminary findings. Psychiatr Danub 2007; 19: 68-75.
109. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsy chotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65: 471-7.
110. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002; 28: 5-16.
111. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-53.
112. Lean ME, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-33.
113. McCarron DA, Oparit S, Chait A, Haynes RB, Kris- Etherton P, Stern JS et al. Nutritional management of cardiovascular risk factors. Arandomized clinical trial. Arch Intern Med 1997; 157: 169-77.